Semnur Pharmaceuticals, Inc. Research and Development Expense
Semnur Pharmaceuticals, Inc. (SMNR) reported Research and Development Expense of $1.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Semnur Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $1.25M, a 148.80% increase year-over-year.
- Semnur Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $1.27M, a 577.01% increase year-over-year.
- Semnur Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $714.00K, a 203.83% increase year-over-year.
- Semnur Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $1.14M, a 390.56% increase year-over-year.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.25M 10-Q · filed 2026-08-10 | $2.52M 10-Q · filed 2026-08-10 | $3.23M derived: sum of 3 quarters · filed 2026-08-10 | $4.37M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $1.27M 10-Q · filed 2026-05-13 | $1.98M derived: sum of 2 quarters · filed 2026-05-13 | $3.12M derived: sum of 3 quarters · filed 2026-05-13 | $3.63M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $714.00K derived: S-1 12 month − 10-Q 9 month · filed 2026-05-12 | $1.86M derived: sum of 2 quarters · filed 2026-05-12 | $2.36M derived: sum of 3 quarters · filed 2026-08-10 | $2.55M S-1 · filed 2026-05-12 |
| 2025-09-30 | $1.14M 10-Q · filed 2025-11-12 | $1.65M derived: sum of 2 quarters · filed 2026-08-10 | $1.83M 10-Q · filed 2025-11-12 | $2.07M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $502.00K 10-Q · filed 2026-08-10 | $689.00K 10-Q · filed 2026-08-10 | $924.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.16M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $187.00K 10-Q · filed 2026-05-13 | $422.00K derived: sum of 2 quarters · filed 2026-05-13 | $655.00K derived: sum of 3 quarters · filed 2026-05-13 | |
| 2024-12-31 | $235.00K derived: S-1 12 month − 10-Q 9 month · filed 2026-05-12 | $468.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.71M S-1 · filed 2026-05-12 | |
| 2024-09-30 | $233.00K 10-Q · filed 2025-11-12 | $1.47M 10-Q · filed 2025-11-12 |